MTX and Steroid as First-line Therapy for aGVHD

Phase 3 Completed 157 enrolled Peking University People's Hospital

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid as first-line therapy for acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (alloHSCT).

Timeline

Start: 2021-06-25
Primary completion: 2022-07-31
Completion: 2022-12-31

Publications

Wang Y, Liu QF, Wu DP, Xu ZL, Han TT, Sun YQ, Huang F, Fan ZP, Xu N, Chen F, Zhao Y, Kong Y, Mo XD, Xu LP, Zhang XH, Liu KY, Huang XJ. Mini-dose methotrexate combined with methylprednisolone for the initial treatment of acute GVHD: a multicentre, randomized trial. BMC Med. 2024 Apr 25;22(1):176. doi: 10.1186/s12916-024-03395-y.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Methotrexate	Small molecule	5 mg/m2	—
Background	Methylprednisolone	Other / unclassified	1 mg/kg	—

MTX and Steroid as First-line Therapy for aGVHD

Summary

Timeline

Publications

Drugs

Indications